Dr. Monk on the FDA Approval of Pembrolizumab in Cervical Cancer

Video

Bradley J. Monk, MD, FACOG, FACS, professor, director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of advanced cervical cancer with disease progression on or after chemotherapy.

Bradley J. Monk, MD, FACOG, FACS, professor, director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of advanced cervical cancer with disease progression on or after chemotherapy.

The approval is based on findings from the phase II KEYNOTE-158 trial, which investigated pembrolizumab in patients with a range of advanced solid tumors who progressed on standard therapy.

Results showed that, at a median follow-up of 11.7 months (range, 0.6-22.7), the overall response rate was 14.3% (95% CI, 7.4-24.1) in 77 PD-L1—positive patients previously treated with more than 1 line of chemotherapy in the metastatic setting. This also included a complete response rate of 2.6% and a partial response rate of 11.7%. Moreover, the median duration of response was not reached, and 91% of responders had a response duration of 6 months or longer.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,